Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 8.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 318,760 shares of the company’s stock after selling 28,832 shares during the period. Jane Street Group LLC owned about 0.21% of Xeris Biopharma worth $908,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Goldstein Advisors LLC boosted its position in shares of Xeris Biopharma by 19.7% during the third quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock worth $87,000 after buying an additional 5,000 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Xeris Biopharma by 10.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,805 shares of the company’s stock worth $130,000 after acquiring an additional 5,291 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Xeris Biopharma by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock valued at $82,000 after acquiring an additional 11,239 shares during the period. Rhumbline Advisers grew its position in Xeris Biopharma by 6.9% in the 2nd quarter. Rhumbline Advisers now owns 189,970 shares of the company’s stock valued at $427,000 after acquiring an additional 12,332 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Xeris Biopharma during the third quarter worth about $35,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Piper Sandler lowered shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Monday, November 11th. HC Wainwright raised their price target on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th.

Xeris Biopharma Price Performance

XERS stock opened at $3.39 on Wednesday. The business’s 50-day moving average is $3.30 and its two-hundred day moving average is $2.83. The firm has a market capitalization of $505.38 million, a P/E ratio of -7.53 and a beta of 2.65. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.69 and a 1 year high of $3.87.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.